Mayo Clinic Proceedings Home

Gene Therapy for Atherosclerotic Cardiovascular Disease: In Response

      We thank Dr Spodick for pointing out that genes may be delivered to the heart via the pericardium. We agree with his comments on the use of pericardial delivery for pharmacological agents and also as a potential medium for gene delivery. How ever, the focus of our article was to discuss progress in approaches to gene therapy of atherosclerosis in humans, and therefore we did not describe animal models. Thus, while pericardial delivery has worked well under a variety of experimental circumstances, we considered this to be beyond the scope of our article.

      Linked Article

      • Gene Therapy for Atherosclerotic Cardiovascular Disease
        Mayo Clinic ProceedingsVol. 75Issue 11
        • Preview
          To the Editor: The review of gene therapy for atherosclerotic disease by O'Brien and Simari1 beautifully summarizes the current state of the art and state of the science. I am slightly perplexed, however, by the omission of intrapericardial therapy, which deposits appropriate agents, including genes and angiogenic factors, directly on the coronary arteries and myocardium. Intrapericardial therapy has worked extremely well under a variety of experimental circumstances (Table 1 and described in detail elsewhere2).
        • Full-Text
        • PDF